Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia

Elias Jabbour, Naval Guastad Daver, Nicholas James Short, Xuelin Huang, Hsiang Chun Chen, Abhishek Maiti, Farhad Ravandi, Jorge Cortes, Simon Abi Aad, Guillermo Garcia-Manero, Zeev Estrov, Tapan Kadia, Susan O'Brien, Bouthaina Dabaja, Carlos Bueso-Ramos, Paolo Strati, Carol Bivins, Sherry Pierce, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Central nervous system (CNS) relapse is uncommon in patients with acute myeloid leukemia (AML) with the use of high-dose cytarabine containing chemotherapy regimens. The clinical and molecular features associated with a higher risk of CNS relapse are not well defined. We assessed the incidence and outcome of CNS relapses among 1245 patients with relapsed/refractory AML referred to our institution between 2000 and 2014. CNS leukemia relapse was observed in 51 patients (4.1%). Using a multivariate regression model and after adjusting for age, FLT3-ITD mutation (OR = 2.33; P =.02) and elevated LDH (>1000 IU/L, OR = 1.99; P =.04) were independent predictive factors for CNS relapse. Patients under 64 years of age with 0, 1, or 2 baseline adverse features had a probability of 3.8%, 7.0%-8.0%, and 13.9% for developing CNS disease, respectively. Our study identifies patients with AML at higher risk for CNS relapse in whom prophylactic CNS therapy may be warranted.

Original languageEnglish (US)
Pages (from-to)924-928
Number of pages5
JournalAmerican Journal of Hematology
Volume92
Issue number9
DOIs
StatePublished - Sep 2017
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Central Nervous System
Recurrence
Central Nervous System Diseases
Cytarabine
Leukemia
Drug Therapy
Mutation
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Jabbour, E., Guastad Daver, N., Short, N. J., Huang, X., Chen, H. C., Maiti, A., ... Kantarjian, H. (2017). Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. American Journal of Hematology, 92(9), 924-928. https://doi.org/10.1002/ajh.24799

Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. / Jabbour, Elias; Guastad Daver, Naval; Short, Nicholas James; Huang, Xuelin; Chen, Hsiang Chun; Maiti, Abhishek; Ravandi, Farhad; Cortes, Jorge; Abi Aad, Simon; Garcia-Manero, Guillermo; Estrov, Zeev; Kadia, Tapan; O'Brien, Susan; Dabaja, Bouthaina; Bueso-Ramos, Carlos; Strati, Paolo; Bivins, Carol; Pierce, Sherry; Kantarjian, Hagop.

In: American Journal of Hematology, Vol. 92, No. 9, 09.2017, p. 924-928.

Research output: Contribution to journalArticle

Jabbour, E, Guastad Daver, N, Short, NJ, Huang, X, Chen, HC, Maiti, A, Ravandi, F, Cortes, J, Abi Aad, S, Garcia-Manero, G, Estrov, Z, Kadia, T, O'Brien, S, Dabaja, B, Bueso-Ramos, C, Strati, P, Bivins, C, Pierce, S & Kantarjian, H 2017, 'Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia', American Journal of Hematology, vol. 92, no. 9, pp. 924-928. https://doi.org/10.1002/ajh.24799
Jabbour, Elias ; Guastad Daver, Naval ; Short, Nicholas James ; Huang, Xuelin ; Chen, Hsiang Chun ; Maiti, Abhishek ; Ravandi, Farhad ; Cortes, Jorge ; Abi Aad, Simon ; Garcia-Manero, Guillermo ; Estrov, Zeev ; Kadia, Tapan ; O'Brien, Susan ; Dabaja, Bouthaina ; Bueso-Ramos, Carlos ; Strati, Paolo ; Bivins, Carol ; Pierce, Sherry ; Kantarjian, Hagop. / Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. In: American Journal of Hematology. 2017 ; Vol. 92, No. 9. pp. 924-928.
@article{2d126fb5b5f94d7a9cced4c7e66259e0,
title = "Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia",
abstract = "Central nervous system (CNS) relapse is uncommon in patients with acute myeloid leukemia (AML) with the use of high-dose cytarabine containing chemotherapy regimens. The clinical and molecular features associated with a higher risk of CNS relapse are not well defined. We assessed the incidence and outcome of CNS relapses among 1245 patients with relapsed/refractory AML referred to our institution between 2000 and 2014. CNS leukemia relapse was observed in 51 patients (4.1{\%}). Using a multivariate regression model and after adjusting for age, FLT3-ITD mutation (OR = 2.33; P =.02) and elevated LDH (>1000 IU/L, OR = 1.99; P =.04) were independent predictive factors for CNS relapse. Patients under 64 years of age with 0, 1, or 2 baseline adverse features had a probability of 3.8{\%}, 7.0{\%}-8.0{\%}, and 13.9{\%} for developing CNS disease, respectively. Our study identifies patients with AML at higher risk for CNS relapse in whom prophylactic CNS therapy may be warranted.",
author = "Elias Jabbour and {Guastad Daver}, Naval and Short, {Nicholas James} and Xuelin Huang and Chen, {Hsiang Chun} and Abhishek Maiti and Farhad Ravandi and Jorge Cortes and {Abi Aad}, Simon and Guillermo Garcia-Manero and Zeev Estrov and Tapan Kadia and Susan O'Brien and Bouthaina Dabaja and Carlos Bueso-Ramos and Paolo Strati and Carol Bivins and Sherry Pierce and Hagop Kantarjian",
year = "2017",
month = "9",
doi = "10.1002/ajh.24799",
language = "English (US)",
volume = "92",
pages = "924--928",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia

AU - Jabbour, Elias

AU - Guastad Daver, Naval

AU - Short, Nicholas James

AU - Huang, Xuelin

AU - Chen, Hsiang Chun

AU - Maiti, Abhishek

AU - Ravandi, Farhad

AU - Cortes, Jorge

AU - Abi Aad, Simon

AU - Garcia-Manero, Guillermo

AU - Estrov, Zeev

AU - Kadia, Tapan

AU - O'Brien, Susan

AU - Dabaja, Bouthaina

AU - Bueso-Ramos, Carlos

AU - Strati, Paolo

AU - Bivins, Carol

AU - Pierce, Sherry

AU - Kantarjian, Hagop

PY - 2017/9

Y1 - 2017/9

N2 - Central nervous system (CNS) relapse is uncommon in patients with acute myeloid leukemia (AML) with the use of high-dose cytarabine containing chemotherapy regimens. The clinical and molecular features associated with a higher risk of CNS relapse are not well defined. We assessed the incidence and outcome of CNS relapses among 1245 patients with relapsed/refractory AML referred to our institution between 2000 and 2014. CNS leukemia relapse was observed in 51 patients (4.1%). Using a multivariate regression model and after adjusting for age, FLT3-ITD mutation (OR = 2.33; P =.02) and elevated LDH (>1000 IU/L, OR = 1.99; P =.04) were independent predictive factors for CNS relapse. Patients under 64 years of age with 0, 1, or 2 baseline adverse features had a probability of 3.8%, 7.0%-8.0%, and 13.9% for developing CNS disease, respectively. Our study identifies patients with AML at higher risk for CNS relapse in whom prophylactic CNS therapy may be warranted.

AB - Central nervous system (CNS) relapse is uncommon in patients with acute myeloid leukemia (AML) with the use of high-dose cytarabine containing chemotherapy regimens. The clinical and molecular features associated with a higher risk of CNS relapse are not well defined. We assessed the incidence and outcome of CNS relapses among 1245 patients with relapsed/refractory AML referred to our institution between 2000 and 2014. CNS leukemia relapse was observed in 51 patients (4.1%). Using a multivariate regression model and after adjusting for age, FLT3-ITD mutation (OR = 2.33; P =.02) and elevated LDH (>1000 IU/L, OR = 1.99; P =.04) were independent predictive factors for CNS relapse. Patients under 64 years of age with 0, 1, or 2 baseline adverse features had a probability of 3.8%, 7.0%-8.0%, and 13.9% for developing CNS disease, respectively. Our study identifies patients with AML at higher risk for CNS relapse in whom prophylactic CNS therapy may be warranted.

UR - http://www.scopus.com/inward/record.url?scp=85025071097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025071097&partnerID=8YFLogxK

U2 - 10.1002/ajh.24799

DO - 10.1002/ajh.24799

M3 - Article

C2 - 28556489

AN - SCOPUS:85025071097

VL - 92

SP - 924

EP - 928

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 9

ER -